Why Cannabis Financing Is Fundamentally Different From Every Other Industry
The cannabis industry's financing landscape is unlike anything else in the American economy. Despite generating an estimated $30 billion in legal sales in 2024 and employing more than 400,000 workers across 38 states with some form of legal cannabis program, the industry remains locked out of the conventional financial system that every other legal business takes for granted. This exclusion is not a minor inconvenience. It is a structural barrier that increases the cost of capital by 200 to 400 percent compared to what similarly sized businesses in other industries pay, and it forces cannabis operators to navigate a complex and sometimes predatory alternative financing market.
The root cause is straightforward. Marijuana remains a Schedule I controlled substance under the federal Controlled Substances Act, and the federal Bank Secrecy Act requires financial institutions to report transactions they know or suspect involve proceeds from illegal activity. While FinCEN guidance issued in 2014 created a framework under which banks can serve cannabis businesses through enhanced due diligence, the compliance burden is significant enough that the vast majority of federally insured banks and credit unions choose not to serve the industry. As of 2024, approximately 812 banks and credit unions nationwide report serving cannabis clients, representing less than 7 percent of the approximately 12,000 federally insured depository institutions in the country.
Without access to conventional banking, cannabis businesses cannot obtain SBA loans, which cap interest rates at approximately 7 to 10 percent. They cannot access commercial lines of credit, which typically cost prime plus 1 to 3 percent. They cannot obtain commercial mortgages at 5 to 7 percent interest rates. And they cannot use the payment processing infrastructure that allows other businesses to accept credit cards at standard merchant discount rates of 2 to 3 percent. Every one of these barriers increases operating costs and reduces the capital available for growth, which is why understanding the financing options that are available, along with their true costs and qualification requirements, is essential for any cannabis operator planning to scale.
How Does Equity Financing Work for Cannabis Companies
Equity financing involves selling ownership shares in the business in exchange for capital. The investor receives a percentage of the company and participates in future profits, either through dividend distributions or through appreciation of their shares when the company is eventually sold or goes public. The business receives capital without taking on debt, meaning there are no mandatory interest payments or principal repayment schedules.
What Terms Should Cannabis Operators Expect in Equity Raises
Cannabis equity financing typically involves selling 15 to 40 percent of the company per round, depending on the stage of the business and the amount of capital raised. Seed-stage cannabis businesses raising $500,000 to $2 million often give up 25 to 40 percent equity because the risk to investors is highest at this stage. Established businesses with $5 million or more in revenue raising $3 million to $10 million in growth capital typically give up 15 to 25 percent because the business has a track record that reduces investor risk.
Valuations in the cannabis industry have undergone dramatic compression since the peak years of 2019 and 2021. In 2021, multi-state operators were trading at 8 to 15 times revenue. By 2024, those same operators were valued at 1 to 3 times revenue, reflecting both the oversupply of cannabis in major markets and the failure of federal legalization to materialize on the timeline investors expected. For a private single-state operator with $5 million in revenue, a realistic valuation range in the current market is $3 million to $10 million, depending on profitability, license value, and market position.
Equity investors in cannabis typically require several non-negotiable terms. Board representation, meaning a seat at the table for major decisions, is standard for investments above $1 million. Liquidation preferences, meaning the investor gets their money back before the founder in a sale, are standard in all institutional rounds. Anti-dilution provisions, meaning the investor's ownership percentage is protected if the company raises future capital at a lower valuation, are increasingly common. And information rights, meaning monthly or quarterly financial reporting, are universal.
When Is Equity Financing the Right Choice for a Cannabis Business
Equity is most appropriate for cannabis businesses that need $2 million or more in capital, have a clear path to 3 to 5 times revenue growth over three to five years, are willing to share control and profits with outside investors, and are building toward an exit event such as an acquisition or public listing. Equity is the wrong choice for businesses that need short-term working capital, are satisfied with their current scale, or have founders who are unwilling to accept outside governance.
What Are the Debt Financing Options Available to Cannabis Operators
Debt financing involves borrowing money that must be repaid with interest over a defined term. Unlike equity, the lender does not receive ownership in the business but does have a contractual right to repayment that is enforceable in court. Cannabis debt financing comes in several forms, each with distinct cost structures and use cases.
How Does Private Credit Work in the Cannabis Industry
Private credit, meaning loans from non-bank lenders such as private debt funds, family offices, and specialty finance companies, is the closest equivalent to traditional bank lending available to cannabis businesses. These lenders are not subject to the same regulatory constraints as banks and can therefore make loans to cannabis operators without violating federal banking laws.
Cannabis private credit terms vary significantly based on the borrower's revenue, profitability, asset base, and state market conditions. Typical terms for a cannabis private credit facility in the current market include loan amounts of $1 million to $25 million, interest rates of 12 to 18 percent annually, terms of 12 to 36 months with monthly interest-only payments and a balloon principal payment at maturity, origination fees of 2 to 4 percent of the loan amount, and personal guarantees from the principals of the borrowing entity.
Most cannabis private credit lenders require the borrower to have a minimum of 12 months of operating history, annual revenue of at least $2 million, and positive EBITDA (or, in the case of 280E-affected businesses, positive adjusted cash flow after taxes). The loan is typically secured by all business assets, including licenses to the extent permitted by state law, real estate, equipment, inventory, and accounts receivable.
The effective cost of cannabis private credit, including interest, origination fees, and any required reserve accounts, typically falls between 16 and 22 percent annually. While this is dramatically more expensive than conventional bank debt at 6 to 10 percent, it is substantially cheaper than equity financing when you account for the ownership dilution that equity requires.
What Is a Sale-Leaseback and Why Is It Popular in Cannabis
A sale-leaseback is a transaction in which a cannabis business that owns its real estate sells the property to an investor and simultaneously enters into a long-term lease to continue occupying the space. The business receives a lump sum equal to 80 to 95 percent of the property's appraised value and converts a fixed, illiquid asset into working capital, while the investor receives a stable, long-term rental income stream secured by both the lease and the underlying real estate.
Sale-leasebacks have become one of the most popular financing structures in cannabis because they offer several advantages over other forms of capital. The proceeds are not classified as debt, so they do not increase the business's leverage ratios or trigger covenant violations on existing loans. The lease payments are deductible as rent expense (or, under 280E, allocable to COGS if the property is used in production), whereas mortgage payments split between non-deductible interest expense and principal that provides no tax benefit under 280E. And the process is typically faster than equity or debt raises, often closing in 45 to 60 days.
The economic terms of cannabis sale-leasebacks depend on the quality and location of the property, the creditworthiness of the tenant, and the remaining term of the cannabis license. Typical terms include purchase prices at 80 to 95 percent of appraised value, lease terms of 10 to 20 years with annual rent escalators of 2 to 3 percent, and cap rates, meaning the ratio of annual rent to purchase price, of 8 to 12 percent. For a cannabis cultivation facility appraised at $5 million, a sale-leaseback might generate $4 million to $4.75 million in proceeds with annual rent of $400,000 to $570,000.
How Does Revenue-Based Financing Serve Cannabis Businesses
Revenue-based financing, sometimes called royalty-based financing, provides capital in exchange for a fixed percentage of future revenue until a predetermined total amount has been repaid. This structure aligns repayment with the business's ability to pay, meaning that in strong months the business repays faster and in slow months the repayment amount decreases.
Cannabis revenue-based financing is typically available in amounts from $250,000 to $5 million, with repayment factors of 1.2 to 1.5 times the amount advanced. This means that a $1 million advance with a 1.35 factor requires total repayment of $1,350,000. Repayment is collected as a fixed percentage of daily or weekly revenue, typically 5 to 15 percent, through a direct debit from the business's bank account or payment processor. The repayment period depends on the business's revenue volume but typically ranges from 6 to 24 months.
The effective annual cost of revenue-based financing varies significantly based on how quickly the advance is repaid. A $1 million advance with a 1.3 factor repaid over 12 months has an effective annual rate of approximately 30 percent. The same advance repaid over 6 months has an effective annual rate of approximately 60 percent. This makes revenue-based financing one of the more expensive forms of cannabis capital on an annualized basis, but the cash flow alignment and lack of collateral requirements make it attractive for businesses that cannot qualify for asset-backed lending.
Revenue-based financing is most appropriate for cannabis dispensaries and brands with consistent, predictable revenue streams. A dispensary generating $200,000 per month in revenue with a 10 percent repayment rate would remit $20,000 per month, repaying a $200,000 advance in approximately 12 months at a total cost of $260,000 to $300,000 depending on the factor. Cultivators and manufacturers with lumpy revenue patterns are less suited to this structure because the revenue-based repayment mechanism creates cash flow pressure during low-revenue months.
What Role Do Invoice Factoring and Inventory Financing Play
Short-term working capital financing fills a critical gap for cannabis businesses that need to bridge the timing difference between when they pay for product and when they collect from customers. The two most common forms are invoice factoring and inventory financing.
How Does Invoice Factoring Work for Cannabis Companies
Invoice factoring involves selling outstanding invoices to a factoring company at a discount. The factoring company advances 70 to 85 percent of the invoice face value immediately and pays the remaining balance, minus a fee, when the invoice is collected from the customer. Fees typically range from 2 to 4 percent of the invoice amount per 30-day period.
For a cannabis brand that ships $500,000 per month in product to dispensaries on net-30 terms, invoice factoring provides immediate access to $350,000 to $425,000 of that revenue. The cost, at 3 percent per 30-day period, is $15,000 per month or $180,000 per year, representing an effective annual rate of 36 percent. This is expensive by conventional business standards but may be justified if the alternative is missing payroll, losing suppliers, or turning down growth opportunities.
Invoice factoring is most common among cannabis brands, cultivators, distributors, and manufacturers, entities that sell wholesale on credit terms. Dispensaries rarely use invoice factoring because their sales are point-of-sale transactions with immediate payment.
How Does Inventory Financing Work in Cannabis
Inventory financing allows cannabis businesses to borrow against the value of their inventory. A lender advances 40 to 60 percent of the wholesale value of eligible inventory, which typically means finished goods that are compliant, tested, and packaged for sale. The lender pays the cannabis business's suppliers directly, and the business repays the lender from the proceeds of inventory sales.
Typical terms include advance rates of 40 to 60 percent of eligible inventory value, fees of 2.5 to 3.5 percent per 30-day period, borrowing terms of up to 90 days, and the requirement that the borrower maintains detailed inventory records reconciled to the state's track-and-trace system. For a dispensary carrying $800,000 in average inventory, inventory financing could provide $320,000 to $480,000 in working capital at a monthly cost of $8,000 to $16,800.
The primary advantage of inventory financing is that it preserves vendor relationships by ensuring timely payment, often at cash-on-delivery pricing that can provide 5 to 10 percent discounts compared to net-30 terms. The discount may partially or fully offset the financing cost, making inventory financing effectively free in the best cases.
What About Equipment Leasing and Cash Advances
How Does Equipment Leasing Work for Cannabis Cultivation
Equipment leasing allows cannabis businesses to acquire cultivation, manufacturing, or processing equipment without a large upfront capital outlay. A leasing company purchases the equipment and leases it to the cannabis business for a defined term, after which the business may purchase the equipment at a residual value, return it, or enter a new lease.
Cannabis equipment leases typically carry interest rates of 8 to 20 percent, with terms of 1 to 7 years. Lease approval is generally based on the business's revenue and operating history rather than personal credit scores, and funding is typically available within 5 to 14 business days. For a cultivator needing $500,000 in LED lighting, environmental controls, and extraction equipment, an equipment lease at 14 percent over 5 years results in monthly payments of approximately $11,600, compared to the full $500,000 cash outlay of purchasing outright.
Under Section 280E, lease payments for equipment used directly in the production of cannabis are allocable to cost of goods sold, making equipment leasing more tax-efficient than purchasing for many cannabis operators. The lease payments reduce COGS dollar-for-dollar, whereas depreciation on purchased equipment requires the same COGS allocation but ties up significantly more cash upfront.
When Should Cannabis Businesses Consider Merchant Cash Advances
Merchant cash advances represent the most expensive and most accessible form of cannabis financing. A cash advance provider purchases a portion of the business's future revenue at a discount, advancing a lump sum with repayment collected as a fixed percentage of daily sales. Factor rates typically range from 1.30 to 1.49, meaning a $100,000 advance costs $130,000 to $149,000 in total repayment. Terms are short, typically 4 to 12 months, and funding is fast, often within one to two business days.
The effective annual cost of a merchant cash advance ranges from 40 to 150 percent depending on the factor rate and repayment speed. This makes cash advances appropriate only for genuine emergencies: preventing license lapse due to unpaid state fees, covering payroll during a temporary cash shortfall, or taking advantage of a time-sensitive business opportunity that will generate returns exceeding the advance cost. They should never be used as ongoing working capital because the compounding cost over multiple advances will destroy the business's profitability.
How Should Cannabis Businesses Choose the Right Financing Structure
The right financing choice depends on the amount of capital needed, the purpose of the capital, the timeline for needing it, and the business's current financial position. For growth capital of $2 million or more with a three to five year deployment horizon, equity financing provides the longest runway and the least cash flow pressure, at the cost of ownership dilution. For real estate monetization without losing operational control, a sale-leaseback provides the best combination of proceeds, cost, and flexibility.
For working capital needs of $500,000 to $5 million with a 12 to 36 month horizon, private credit offers the most institutional-quality terms. For short-term cash flow bridging under $500,000, invoice factoring or inventory financing provides the fastest and most operationally aligned solution. And for emergency capital needed within 48 hours, a merchant cash advance may be the only option, but should be refinanced into a lower-cost structure as quickly as possible.
Regardless of the financing structure chosen, cannabis businesses must have audit-ready financial records, accurate tax returns, clean compliance histories, and documented operational processes. Lenders and investors in the cannabis space perform extensive due diligence, and the businesses that receive the best terms are the ones that can demonstrate financial discipline and operational transparency. At Northstar, we work with cannabis operators to build the financial infrastructure that not only supports day-to-day operations but also positions the business to access capital on the best available terms when growth opportunities arise.